Study on the Efficacy and Safety of Mecobalamin in Preventing Taxane-related Peripheral Neuropathy

Inclusion Criteria: 1. Histologically or cytologically confirmed solid tumors, including but not limited to breast cancer, lung cancer, gastric cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer, and melanoma; 2. Age ≥18 years; 3. Scheduled to receive adjuvant or neoadjuvant taxane-based chemotherapy (including paclitaxel, nab-paclitaxel, or docetaxel; as monotherapy or in combination) for early-stage disease, or has advanced disease with no prior chemotherapy; 4. Life expectancy ≥3 months; 5. ECOG performance status 0-2; 6. Adequate major organ function (cardiac, hepatic, renal, and bone marrow function); 7. Willing and able to provide written informed consent and comply with study procedures. Exclusion Criteria: 1. Severe impairment of major organ function such that the participant cannot tolerate standard-dose chemotherapy; 2. Pre-existing peripheral neuropathy or a history of peripheral neuropathy; 3. Skin conditions (e.g., severe palmoplantar keratoderma, active skin infection) that may interfere with assessment of CIPN symptoms; 4. Recent use of medications that may alleviate CIPN symptoms; 5. Inability to swallow, intestinal obstruction, or other conditions that may affect drug absorption; 6. Known hypersensitivity or allergy to mecobalamin; 7. Pregnant or breastfeeding women.